 CD11a is one of the two components, along with CD18, which form lymphocyte function-associated antigen-1.Efalizumab acts as an immunosuppressant by binding to CD11a but was withdrawn in 2009 because it was associated with severe side effects.CD11a has been shown to interact with ICAM-1.